Emerging drugs for the treatment of gastrointestinal stromal tumors

• Published in: Expert opinion on emerging drugs Vol. 26; no. 1; p. 53
• Main Authors: Pilco-Janeta, Daniel F, García-Valverde, Alfonso, Gomez-Peregrina, David, Serrano, César
• Format: Journal Article
• Language: English
• Published: England 02.01.2021
• Subjects: imatinib; GIST; Avapritinib; sarcoma; ripretinib; tyrosine kinase inhibitor
• ISSN: 1744-7623
• DOI: 10.1080/14728214.2021.1896704

Oncogenic activation of KIT or PDGFRA receptor tyrosine kinases is the crucial event in gastrointestinal stromal tumor (GIST) biology. Seminal works during the past two decades have underscored, first, the continuous relevance of KIT/PDGFRA oncogenic signaling after progression to targeted inhibition; second, the heterogeneity of KIT/PDGFRA acquired mutations, that cannot be efficiently suppressed by any given tyrosine kinase inhibitor (TKI); and third, the presence of specific mutants highly resistant to all approved therapies. This review discusses treatment options in advanced/metastatic GIST, including a detailed dissection of ripretinib and avapritinib, the two novel small molecule inhibitors approved by the Food and Drug Administration in 2020. The three only therapeutic options since 2012 for metastatic GIST patients were imatinib, sunitinib, and regorafenib. Although imatinib was highly effective in treatment-naïve GIST, the benefit of second- and third-line sunitinib and regorafenib was modest, thus emphasizing the medical need for new treatment options. Ripretinib, a switch control inhibitor with broad anti-KIT/PDGFRA activity, has been approved as ≥4th line in GIST after progression to all standard therapies. Avapritinib, a type I TKI highly specific against the multi-resistant PDGFRA D842V mutation, is approved in this specific subset of GIST patients.